Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

x

NEW WHITE PAPER: Applications of HUB Tumor Organoids in Oncology Drug Development

Learn more about PDX-derived tumor organoids (PDXO) developed using HUB protocols, as robust in vitro models to improve the predictivity and speed of preclinical drug discovery. Review the main applications of 3D PDXO including large-scale drug screening, in vivo model selection, and in silico drug discovery.

WEBINAR: 3 Strategies to Identify Clinically Predictive Biomarkers in the Preclinical Space

January 15th, 2020 10am/4pm/10pm ET

Join Mike Batey to learn how to apply systems biology in early stage drug development for biomarker discovery and validation. Review 3 case studies exploring novel strategies to identify and utilize biomarkers using translational preclinical models, including using in vitro models to uncover genetic signatures of response and in vivo PDX to dissect drug MoA and guide clinical trial design.

ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

NEW WHITE PAPER: How to Assess Immunotherapy Toxicity using NHPs

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

ON DEMAND WEBINAR: Assessing Immunotherapy Toxicity in NHPs

Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

NEW WHITE PAPER: Unlock the Full Power of MCTs through Advanced Statistical Analysis

Learn how to optimize PDX mouse clinical trial design, use, and data output by moving beyond traditional analyses to a robust statistical framework. Explore case studies applying our published linear mixed models to enhance MCT study design, drug efficacy quantification, biomarker discovery and validation, as well as reinterpretation of clinical trial results.

NEW WHITE PAPER! HUB Organoid Technology: Advantages in 3D In Vitro Modeling

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

ON DEMAND WEBINAR: Preclinical Obesity Research: Best Practice in Model Selection and Study Design

Presented by Dr Fred Beasley this webinar explores how to select the most appropriate models for your preclinical obesity studies, including polygenic vs monogenic models and recommendations based on drug modes of action. We also review best practice in obesity study design to maximize data outcomes.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

December 3, 2019

Top 12 Questions: Applications of PDXO

Review the top 12 questions on PDX-derived organoid (PDXO) utilities from our recent webinar, answered by Dr. Rajendra Kumari, Global Head of Scientific Communication.

Read More

December 3, 2019

Top 12 Questions: Applications of PDXO

Review the top 12 questions on PDX-derived organoid (PDXO) utilities from our recent webinar,...

Read More

November 22, 2019

The Importance of Companion Diagnostics

Explore the importance of companion diagnostics (CDx) and the benefits of their early adoption...

Read More

November 5, 2019

Cancer Biomarkers: Improving Detection and Treatment

Explore the three main types of cancer biomarkers and their main uses in cancer diagnosis,...

Read More

Upcoming Events


December 11, 2019

Lunch and Learn: Patient-Derived Experimental Models for Translational Cancer Research

San Diego, CA


December 11-14, 2019

ESMO Immuno-Oncology Congress 2019

Geneva, Switzerland


January 15, 2020

Webinar: 3 Strategies to Identify Clinically Predictive Biomarkers in the Preclinical Space


January 22-24, 2020

4th PREDiCT: Tumor Models San Francisco

San Francisco, CA


January 25-29, 2020

SLAS

San Diego, CA